Lumexa Imaging Holdings, Inc. LMRI R2KPHARMA
Company Overview
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.
Recent Developments
- Dec 2025 Revenue of $1.02B (+7.8% YoY); net profit $-47.10M.
- Trailing 12 Months Year-on-year growth — revenue +3.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.55% |
| 1 Year: | 3.10% |
Stock Price Performance
| 1 Year: | -34.23% |
| 6 Months: | -17.70% |
| 3 Months: | +43.29% |
| 1 Month: | +6.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)58.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 34.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LMRI Lumexa Imaging Holdings, Inc. R2KPHARMA | 12.18 | -31.23 | $1.17B | 0.00% | 1.69% | -8.04% | 4.55% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 248.03M | 245.00M | 267.73M | 252.54M |
| Cost of Revenue | 226.46M | 208.40M | 225.62M | 217.75M |
| Gross Profit | 21.57M | 36.60M | 42.12M | 34.78M |
| Operating Expenses | 29.97M | 26.54M | 49.59M | 30.26M |
| Operating Income | -8.40M | 10.06M | -7.47M | 4.53M |
| EBITDA | 28.94M | 38.33M | 19.00M | 33.29M |
| Interest Expense | 31.39M | 29.85M | 28.02M | 16.33M |
| Pretax Income | -16.03M | -4.31M | -25.26M | 3.08M |
| Tax Provision | 9.03M | 3.38M | 3.43M | 1.36M |
| Net Income | -25.06M | -7.69M | -28.69M | 1.72M |
| Diluted EPS | - | -0.08 | -0.38 | 0.02 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 935.92M | 948.87M | 1.02B |
| Cost of Revenue | 836.96M | 852.61M | 865.52M |
| Gross Profit | 98.97M | 96.26M | 157.56M |
| Operating Expenses | 111.80M | 112.53M | 130.83M |
| Operating Income | -12.83M | -16.26M | 26.73M |
| EBITDA | 94.51M | 113.96M | 141.71M |
| Interest Expense | 141.69M | 136.03M | 118.54M |
| Pretax Income | -119.25M | -79.19M | -32.22M |
| Tax Provision | 2.98M | 14.91M | 14.88M |
| Net Income | -122.23M | -94.10M | -47.10M |
| Diluted EPS | -1.76 | -1.35 | -0.66 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 1.67B | 1.67B | 1.76B |
| Current Assets | 166.77M | 172.52M | 227.26M |
| Cash & Equivalents | 20.19M | 26.13M | 58.83M |
| Inventory | - | - | - |
| Receivables | 124.12M | 130.35M | 131.84M |
| Total Liabilities | 1.47B | 1.51B | 1.18B |
| Current Liabilities | 161.12M | 173.66M | 179.19M |
| Long Term Debt | 1.18B | 1.19B | 819.03M |
| Total Debt | 1.30B | 1.31B | 962.50M |
| Total Equity | 198.43M | 161.65M | 586.12M |
| Shares Outstanding | 94.57M | 94.57M | 96.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 37.51M | 40.73M | 17.07M |
| Investing Cash Flow | -29.66M | -22.28M | -20.96M |
| Financing Cash Flow | -8.77M | -12.50M | 36.58M |
| Capital Expenditure | -24.01M | -27.77M | -23.48M |
| Free Cash Flow | 13.51M | 12.95M | -6.40M |
| Net Change in Cash | -912.00K | 5.95M | 32.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 10.6% | 10.1% | 15.4% |
| Operating Margin % | -1.4% | -1.7% | 2.6% |
| Net Margin % | -13.1% | -9.9% | -4.6% |
| ROE % | -61.6% | -58.2% | -8.0% |
| ROCE % | -0.8% | -1.1% | 1.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brown Advisory Inc. | 6.01% | 5.78M | $66.50M |
| 2 | Massachusetts Financial Services Co. | 3.59% | 3.45M | $39.75M |
| 3 | Think Investments LP | 2.66% | 2.56M | $29.46M |
| 4 | Jupiter Topco LLC | 2.24% | 2.15M | $24.76M |
| 5 | Blackrock Inc. | 1.46% | 1.40M | $16.09M |
| 6 | JPMORGAN CHASE & CO | 1.20% | 1.15M | $13.29M |
| 7 | Vanguard Capital Management LLC | 1.11% | 1.07M | $12.32M |
| 8 | Goldman Sachs Group Inc | 0.84% | 807.43K | $9.29M |
| 9 | Royce & Associates LP | 0.82% | 789.04K | $9.08M |
| 10 | Schonfeld Strategic Advisors Llc | 0.80% | 768.89K | $8.85M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LMRI
Breakeven Is Near for Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQam1xRXJQeUN1T2c5c3d6SmN4bkZwNmtxdmd1WV90YUhOSGxKNVE2YzduTUlrdWNZVzliUmdWQUNLOWdWNFRxNzRMWVFjbGZIdXBVZWo1NndKQWFnbWhoclNlcjE5bVZUQ0xvclM4OHRiaTRmYlFGdU9qci1HSllJWFdSRXBZOEUtTURVbk…
Bank of America Corp DE Raises Stock Position in Lumexa Imaging Holdings, Inc. $LMRI - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNX0FxRk5lczJqN3J3VndCUmN4T0lITWU4SmJNZ3JzeVBWRmxMQ0RVcnM1NHFseXNDc1pxZWx1ZC1KVXNndTdpbGx6OGNnZGl4dDQ3dTRVNjcyaU1OWjk3Qlhxb2FvdTNsX3REVkM3cGphQ0FOQ2FKVmhxT2ExQWlrU3UxMndKLUh1Yi0xcW…
Lumexa Imaging (LMRI) Stock Jumps As Profit Arrives But Margin Doubts Persist - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQZ1V6X3k2TTIwaXJNUTFUREJzNUFVenIyS1ZaSVdzaTZxTWI4WlFULTdybkFYTTIyeVV5OHkxSWFvTDRtb2pNX0pVcWZ0X0VlWDdtQklqaXdRSWpZOE4zS1V0VVlSZ1lOdFBBUHluTXp6SVlmVHdCTnE1ZFZKamRhV0o2OFVEbjUzM0EwZ3…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1EWU1WZXhiTnpheEpCWDNPaWREenNZV2t2cnJfbEgwdWpIYUgyTzZ2RGdGOE9CVlpLSDE5dlQzRTd4LVZuNHpRWERWa0ZCVnlX?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI) Stock Price, News & Analysis - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9acW1Lbm5tYVJoVDQwMWlCMU5FMjEwajVVMUZNQ1lFc3RRRXg3M25iWWw0Qk5lNmI1aVBIVGViUUtmWVNLbUpxc3g5ZW1vNGVKOWVYT0hB?oc=5" target="_blank">Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ:…
LUMEXA IMAGING HOLDINGS ($LMRI) Releases Q2 2026 Earnings, Stock Rises - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQV1R2bG9QTjZGMVZCa210TERxc2trTjhHcnlIdG1Gbk1PcTFxNDNpcGoyOVBQQmZVLUtvUUF0dW8zc3c2dU1DeWxQTmltNTg3Y1FVOUo5RHBRVEQ3WWtHZXZEQ3YyX1l6UF9Mb1gyb0FpbjlxT18wZldFQ0ZQWGRxQm5WcEkyVjF5ZFpyNE…
LMRI — Frequently Asked Questions
What is the current share price of Lumexa Imaging Holdings, Inc. (LMRI)?
As of 2026-09-07 16:24 PDT, Lumexa Imaging Holdings, Inc. (LMRI) trades at $12.18 on NasdaqGS. Its 52-week range is $6.77 to $18.53.
What is the market capitalisation of LMRI?
Lumexa Imaging Holdings, Inc. (LMRI) has a market capitalisation of $1.17B on NasdaqGS.
What is the P/E ratio of LMRI?
LMRI trades at a trailing price-to-earnings (P/E) ratio of -31.23. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.86.
What is the return on equity (ROE) of LMRI?
LMRI has a return on equity (ROE) of -8.04%. Its return on capital employed (ROCE) is 1.69%.
Is LMRI a good stock to buy?
This page provides a data-driven analysis of Lumexa Imaging Holdings, Inc. (LMRI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.